Tutkimus lebrikitsumabista aikuisilla, joilla on monivuotinen allerginen nuha (VALMIS-1)
Vaihe 3, monikeskus, satunnaistettu, kaksoissokko, lumekontrolloitu, rinnakkaisryhmätutkimus lebrikitsumabin/LY3650150:n tehon ja turvallisuuden arvioimiseksi aikuisilla potilailla, joilla on monivuotinen allerginen nuha
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with perennial allergic rhinitis.
Participants can expect study participation to last up to 29.5 months.
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Vaihe 3
Yhteystiedot ja paikat
Opiskelupaikat
-
-
-
Brussels, Belgia, 1070
- Hôpital Erasme, Service Pharmacie
-
Erpent, Belgia, 5101
- Pneumocare
-
Ghent, Belgia, 9000
- UZ Gent
-
Leuven, Belgia, 3000
- UZ Leuven, Pharmacy
-
Liège, Belgia, 4000
- Hôpital de la Citadelle
-
-
-
-
-
Busan, Etelä -Korea, 48108
- Inje University Haeundae Paik Hospital
-
Incheon, Etelä -Korea, 21565
- B1F, Pharmacy department, Gachon University Gil Medical Center
-
Seongnam-si, Etelä -Korea, 13620
- Seoul National University Bundang Hospital
-
Seoul, Etelä -Korea, 03722
- Severance Hospital, Yonsei University Health System
-
Seoul, Etelä -Korea, 05278
- Kyunghee University Hospital at Gangdong
-
Seoul, Etelä -Korea, 6273
- Gangnam Severance Hospital 211
-
Seoul, Etelä -Korea, 7061
- SMG-SNU Boramae Medical Center
-
Seoul, Etelä -Korea, 8308
- Clinical trial Pharmacy
-
-
-
-
-
Beijing, Kiina, 100032
- Internal Medicine Building
-
Beijing, Kiina, 100730
- Department of Nasal Allergy
-
Changsha, Kiina, 410013
- The Third Xiangya Hospital of Central South University
-
Guangzhou, Kiina, 510000
- GCP Pharmacy
-
Hangzhou, Kiina, 310014
- Zhejiang People's Hospital
-
Jingzhou, Kiina, 434020
- Jingzhou Central Hospital
-
Nanchang, Kiina, 330006
- The First Affiliated Hospital of Nanchang University
-
Nanchang, Kiina, 330006
- The Second Affiliated Hospital of Nanchang University
-
Nanning, Kiina, 530021
- People's Hospital of Guangxi Zhuang Autonomous Region
-
Nanning, Kiina, 530021
- The First Affiliated Hospital of Guangxi Medical University
-
Shanghai, Kiina, 200065
- Tongji Hospital
-
Wuhan, Kiina, 430060
- Renmin Hospital of Wuhan University
-
Wuhan, Kiina, 430014
- Outpatient building
-
Wuhan, Kiina, 430022
- Outpatient Department, Union Hospital
-
Yangzhou, Kiina, 225001
- Northern Jiangsu People's Hospital
-
Yangzhou, Kiina, 225012
- Yangzhou University
-
Zhongshan, Kiina, 528403
- Zhongshan City People's Hospital
-
-
-
-
-
Kielce, Puola, 25-355
- Polimedica PTG Kielce
-
Krakow, Puola, 31-513
- Centrum Medyczne Promed ul. Olszańska 5G
-
Krakow, Puola, 31-623
- Malopolskie Centrum Alergologii
-
Lodz, Puola, 90-302
- gab. 114, ul. inż. pilota Wigury
-
Lublin, Puola, 20-412
- ETG Lublin
-
Piła, Puola, 64-920
- Centrum Alergologii Teresa Hofman Sp z.o.o.
-
Rzeszów, Puola, 35-205
- EMED Centrum Usług Medycznych
-
Skierniewice, Puola, 96-100
- ClinMedica Research
-
Tarnów, Puola, 33-100
- Alergo-Med Specjalistyczna Przychodnia Lekarska Sp Z O.O.
-
Warsaw, Puola, 02-793
- ETG Warszawa
-
Wroclaw, Puola, 53-201
- ALL-MED - Specjalistyczna Opieka Medyczna
-
-
-
-
-
Berlin, Saksa, 10117
- Charité - Universitätsmedizin Berlin Klinik für Dermatologie
-
Dresden, Saksa, 1307
- Universitätsklinikum Carl Gustav Carus an der TU
-
Dresden, Saksa, 1139
- Praxis für HNO und Allergologie
-
Frankfurt am Main, Saksa, 60596
- IKF Pneumologie
-
Heidelberg, Saksa, 69115
- Siteworks - Zentrum für klinische Studien Heidelberg
-
Marburg, Saksa, 35043
- Universitätsklinik Marburg,Hals-, Nasen- und Ohrenklinik, Sektion Rhinologie und Allergologie
-
Weisbaden, Saksa, 65183
- Zentrum für Rhinologie und Allergologie
-
-
-
-
California
-
Huntington Beach, California, Yhdysvallat, 92648
- Allergy and Asthma Specialists Medical Group
-
Inglewood, California, Yhdysvallat, 90301
- 310 Clinical Research
-
Laguna Niguel, California, Yhdysvallat, 92677
- Allergy & Asthma Associates of Southern California dba. Southern California Research
-
San Diego, California, Yhdysvallat, 92123
- Allergy and Asthma
-
-
Colorado
-
Colorado Springs, Colorado, Yhdysvallat, 80907-6231
- Asthma and Allergy Associates, PC
-
-
Florida
-
Tallahassee, Florida, Yhdysvallat, 32308
- Allergy and Asthma Diagnostic Center
-
Tampa, Florida, Yhdysvallat, 33613
- University of South Florida
-
-
Illinois
-
Chicago, Illinois, Yhdysvallat, 60611
- Northwestern University
-
River Forest, Illinois, Yhdysvallat, 60305
- Asthma Allergy Center of Chicago
-
-
Kentucky
-
Lexington, Kentucky, Yhdysvallat, 40509
- Bluegrass Allergy Research
-
-
Michigan
-
Ypsilanti, Michigan, Yhdysvallat, 48197
- Respiratory Medicine Research Institute of Michigan, PLC
-
-
Minnesota
-
Minneapolis, Minnesota, Yhdysvallat, 55402
- Clinical Research Institute
-
-
Missouri
-
Columbia, Missouri, Yhdysvallat, 65212
- University of Missouri Hospital
-
St Louis, Missouri, Yhdysvallat, 63141
- Allergy and Asthma Consultants
-
-
Nebraska
-
Bellevue, Nebraska, Yhdysvallat, 68123
- Asthma and Allergy Center
-
-
New Jersey
-
Belleville, New Jersey, Yhdysvallat, 07109
- Circuit Clinical/Hudson-Essex Allergy
-
Hamilton, New Jersey, Yhdysvallat, 08619
- Circuit Clinical/Mercer Allergy and Pulmonary Associates
-
Teaneck, New Jersey, Yhdysvallat, 07666
- Dr. Patrick Perin
-
-
New York
-
Horseheads, New York, Yhdysvallat, 14845
- Smith Allergy and Asthma
-
-
North Carolina
-
Asheville, North Carolina, Yhdysvallat, 28803
- Allergy Partners
-
-
Ohio
-
Cincinnati, Ohio, Yhdysvallat, 45236
- Bernstein Clinical Research Center, LLC
-
-
Oregon
-
Portland, Oregon, Yhdysvallat, 97202
- Northwest Research Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Yhdysvallat, 15241
- Allergy and Clinical Immunology Associates
-
-
Texas
-
Dallas, Texas, Yhdysvallat, 75231
- AARA Research Center
-
Kerrville, Texas, Yhdysvallat, 78028
- Kerrville Allergy and Asthma Associates
-
-
Wisconsin
-
Greenfield, Wisconsin, Yhdysvallat, 53228
- Allergy, Asthma & Sinus Center
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Physician-diagnosed perennial allergic rhinitis (PAR).
- Has a positive skin prick test (SPT) with indoor allergens and/or positive serum antigen-specific immunoglobulin E (IgE) for indoor allergens ≥0.70 kU/L, utilizing a validated assay (central laboratory).
- The participant must have clinical symptoms at study entry associated with positive perennial allergen as tested by the SPT or a positive serum antigen-specific IgE test.
- A participant who has a known history of dermatographism or identified during the SPT may participate in this study with a positive serum antigen-specific IgE test.
- Participants who have concomitant asthma must be stable in the 3 months prior to screening using permitted regular asthma treatment.
Exclusion Criteria:
-
Have received a dose of lebrikizumab.
-
Is currently on AIT subcutaneous immunotherapy or sublingual immunotherapy. However, individuals who discontinued subcutaneous or sublingual immunotherapy for ≥3 years prior to randomization are eligible.
-
Have received treatment with any rescue medication during the run-in period.
-
Have received treatment with any biologic or systemic immunosuppressants, including Janus Kinase inhibitors (JAK) for inflammatory disease or autoimmune disease prior to the baseline visit:
- Any current or prior use of biologics indicated for asthma or AD are prohibited.
- B cell-depleting biologics, including rituximab, within 6 months.
- Other biologics within 5 half-lives (if known) or 8 weeks, whichever is longer.
- Systemic immunosuppressants, including JAK inhibitors, within 4 weeks prior to baseline.
-
Have a history of seasonal worsening of AR and if the seasonal worsening is expected during the 4-week run-in period, the first 16 weeks after randomization, or during the last 8 weeks of the maintenance period.
-
Anticipates significant changes in their daily environmental exposure.
-
Has a known history of recurrent acute or chronic sinusitis.
-
Female participant who is pregnant, breastfeeding or is planning to become pregnant or to breastfeed during the study.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Kaksinkertainen
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Lebrikizumab every 2 weeks (Q2W)/ every 4 weeks (Q4W)
Lebrikizumab will be given as a subcutaneous (SC) injection. Participants will receive background therapy with intranasal corticosteroids (INCS). |
Administered SC Administered as intranasal spray |
|
Kokeellinen: Lebrikizumab Q2W/every 8 weeks (Q8W)
Lebrikizumab will be given as an SC injection. Participants will receive background therapy with INCS. |
Administered SC Administered as intranasal spray |
|
Placebo Comparator: Placebo Q2W/Q4W
Placebo matching Lebrikizumab will be given as an SC injection. Participants will receive background therapy with INCS. |
Administered SC Administered as intranasal spray |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Mean Change From Baseline (CFBL) in Total Nasal Symptom Score (TNSS) at Week 16
Aikaikkuna: Baseline, Week 16
|
Total nasal symptom score was a composite of 4 symptoms (rhinorrhea, nasal congestion, nasal itching and sneezing), each symptom was scored on a scale of 0 = none, 1 = mild, 2 = moderate, 3 = severe. The total score ranged from 0 to 12. The higher the score was, the more severe the symptoms were. |
Baseline, Week 16
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Mean CFBL in Rhinoconjunctivitis Quality of Life Questionnaire Standardized Version [RQLQ(S)] Activities Domain at Week 16
Aikaikkuna: Baseline, Week 16
|
The RQLQ includes 28 questions (completed between 10-15 min). Participants are asked to recall their experiences during the previous week and to respond to each question on a 7-point scale. The RQLQ score ranges from 0 to 6 (0 = no impairment, 6 = severe impairment). |
Baseline, Week 16
|
|
Mean CFBL in RQLQ(S) Activities Domain at Week 56
Aikaikkuna: Baseline, Week 56
|
The RQLQ includes 28 questions (completed between 10-15 min). Participants are asked to recall their experiences during the previous week and to respond to each question on a 7-point scale. The RQLQ score ranges from 0 to 6 (0 = no impairment, 6 = severe impairment) |
Baseline, Week 56
|
|
Mean CFBL in RQLQ(S) Total Score at Week 16
Aikaikkuna: Baseline, Week 16
|
The RQLQ includes 28 questions (completed between 10-15 min). Participants are asked to recall their experiences during the previous week and to respond to each question on a 7-point scale. The RQLQ score ranges from 0 to 6 (0 = no impairment, 6 = severe impairment). |
Baseline, Week 16
|
|
Mean CFBL in RQLQ(S) Total Score at Week 56
Aikaikkuna: Baseline, Week 56
|
The RQLQ includes 28 questions (completed between 10-15 min). Participants are asked to recall their experiences during the previous week and to respond to each question on a 7-point scale. The RQLQ score ranges from 0 to 6 (0 = no impairment, 6 = severe impairment). |
Baseline, Week 56
|
|
Mean CFBL in TNSS at Week 4
Aikaikkuna: Baseline, Week 4
|
Total nasal symptom score was a composite of 4 symptoms (rhinorrhea, nasal congestion, nasal itching and sneezing), each symptom was scored on a scale of 0 = none, 1 = mild, 2 = moderate, 3 = severe. The total score ranged from 0 to 12. The higher the score was, the more severe the symptoms were. |
Baseline, Week 4
|
|
Mean CFBL in TNSS at Week 56
Aikaikkuna: Baseline, Week 56
|
Total nasal symptom score was a composite of 4 symptoms (rhinorrhea, nasal congestion, nasal itching and sneezing), each symptom was scored on a scale of 0 = none, 1 = mild, 2 = moderate, 3 = severe. The total score ranged from 0 to 12. The higher the score was, the more severe the symptoms were. |
Baseline, Week 56
|
|
Mean CFBL in Postnasal Drip Score at Week 16
Aikaikkuna: Baseline, Week 16
|
Postnasal drip is mucus drainage down the throat, as part of their Allergic Rhinitis (AR), will be rated by participants using a 4-point scale, where 0 corresponds to no symptoms and 3 corresponds to severe symptoms. Study participants are asked to record the severity of their postnasal drip, at its worst, for the previous 24 hours. |
Baseline, Week 16
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Opintojohtaja: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
- Immuunijärjestelmän sairaudet
- Hengityselinten sairaudet
- Hengitysteiden yliherkkyys
- Yliherkkyys, välitön
- Yliherkkyys
- Nenän sairaudet
- Otorinolaryngologiset sairaudet
- Nuha
- Nuha, allerginen
- Nuha, allerginen, monivuotinen
- Terveyspalveluiden hallinto
- Terveydenhuollon laatu, saatavuus ja arviointi
- Terveydenhuollon laatu
- Laatuindikaattorit, terveydenhuolto
- Hoidon taso
Muut tutkimustunnusnumerot
- 18789
- J2T-MC-KGBT (Muu tunniste: Eli Lilly and Company)
- 2023-508817-18-00 (Muu tunniste: EU Clinical Trial Number)
- 2023 (Yhdysvaltain NIH-apuraha/sopimus)
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
Anonymized individual participant level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD-jaon aikakehys
Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
IPD-jaon käyttöoikeuskriteerit
A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement
IPD-jakamista tukeva tietotyyppi
- STUDY_PROTOCOL
- MAHLA
- CSR
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .